In vivo studies show that the growth of both XBP1s-transgenic mice and human MM cell lines is dependent on gp96, indicating that inhibiting gp96 could represent a promising therapeutic strategy against MM [143]. This evidence concerns the gene HSP90B1 and Miyoshi myopathy.